3.9 Review

Therapeutic Applications of DNA and RNA Aptamers

Journal

OLIGONUCLEOTIDES
Volume 19, Issue 3, Pages 209-222

Publisher

MARY ANN LIEBERT, INC
DOI: 10.1089/oli.2009.0199

Keywords

-

Funding

  1. NCI NIH HHS [R01 CA138503] Funding Source: Medline
  2. NHLBI NIH HHS [T32 HL007344] Funding Source: Medline
  3. NATIONAL CANCER INSTITUTE [R01CA138503] Funding Source: NIH RePORTER
  4. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007344] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Structured single-stranded nucleic acids, or aptamers, bind target molecules with high affinity and specificity, which translates into unique therapeutic possibilities. Currently, aptamers can be identified to most proteins, including blood-clotting factors, cell-surface receptors, and transcription factors. Chemical modifications to the oligonucleotides enhance their pharmacokinetics and pharmacodynamics, thus extending their therapeutic potential. Several aptamers have entered the clinical pipeline for applications and diseases such as macular degeneration, coronary artery bypass graft surgery, and various types of cancer. Furthermore, the functional repertoire of aptamers has expanded with the descriptions of multivalent agonistic aptamers and aptamers-siRNA chimeras. This review highlights those aptamers and aptamer-based approaches with particular likelihood of achieving therapeutic application.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.9
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available